Britannia Life Sciences Inc.
BLSIF
$0.0666
-$0.0114-14.62%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -34.55% | -50.33% | -26.60% | -23.42% | -16.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.55% | -50.33% | -26.60% | -23.42% | -16.37% |
| Cost of Revenue | 17.26% | -17.40% | -37.64% | -36.99% | -32.15% |
| Gross Profit | -17.12% | -42.95% | -54.85% | -50.92% | -44.90% |
| SG&A Expenses | -18.58% | -28.40% | -43.03% | -37.76% | -21.26% |
| Depreciation & Amortization | 5.61% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -31.28% | -41.21% | -18.44% | -12.90% | 1.46% |
| Operating Income | -86.96% | -94.68% | -67.83% | -62.05% | -78.11% |
| Income Before Tax | -534.74% | -222.99% | -195.56% | -182.64% | -84.41% |
| Income Tax Expenses | 9.06% | -38.94% | 265.30% | 153.68% | 188.98% |
| Earnings from Continuing Operations | -1,078.15% | -275.51% | -209.24% | -198.08% | -91.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -242.82% | -557.32% | -19.78% | 104.88% | 112.78% |
| Net Income | 63.08% | 57.23% | -566.69% | -751.27% | -456.02% |
| EBIT | -86.96% | -94.68% | -67.83% | -62.05% | -78.11% |
| EBITDA | -77.83% | -91.08% | -68.18% | -60.55% | -71.54% |
| EPS Basic | 60.57% | 54.59% | -565.38% | -740.38% | -451.43% |
| Normalized Basic EPS | -10,900.00% | -373.08% | -422.73% | -256.25% | 110.00% |
| EPS Diluted | 60.57% | 54.59% | -565.38% | -740.38% | -451.43% |
| Normalized Diluted EPS | -10,900.00% | -373.08% | -422.73% | -256.25% | 110.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.01% | 0.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |